PD-1 blockade reprograms antiviral immunity and reduces the HIV reservoir - Nature

PD-1 blockade reprograms antiviral immunity and reduces the HIV reservoir  Nature

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 the...

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy  Nature

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment - fda.gov

Women and HIV: Get the Facts on HIV Testing, Prevention, and Treatment  fda.gov

London patient remains HIV-free after 2.5 years off treatment - Aidsmap

London patient remains HIV-free after 2.5 years off treatment  Aidsmap

A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV - ScienceAlert

A Hidden Defense Inside Llamas Could Be The Secret to Fighting HIV  ScienceAlert

WHO HIVResNet HIV drug resistance laboratory operational framework - World Health Organization (WHO)

WHO HIVResNet HIV drug resistance laboratory operational framework  World Health Organization (WHO)

Some children who start antiretrovirals very early may control HIV after stopping treatment - Aid...

Some children who start antiretrovirals very early may control HIV after stopping treatment  Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV - Aidsmap

After viral rebound, dolutegravir-based treatment more likely to suppress HIV  Aidsmap

T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection - ...

T cells is associated with enhanced antiviral potential and natural control of HIV-1 infection  Nature

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatme...

São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment  Aidsmap

Scientists use gene-edited stem cells to treat HIV — with mixed success - Nature

Scientists use gene-edited stem cells to treat HIV — with mixed success  Nature

Child with HIV maintains viral suppression for three years off treatment - Aidsmap

Child with HIV maintains viral suppression for three years off treatment  Aidsmap

Reappearance of HIV in "Mississippi Baby" poses questions for early treatment - Aidsmap

Reappearance of HIV in "Mississippi Baby" poses questions for early treatment  Aidsmap

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two year...

Nearly a third of babies with HIV given ART very soon after birth have no HIV antibodies two years later  Aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel? - Aidsmap

Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel?  Aidsmap

Yes, the same life expectancy as HIV-negative people, but far fewer years in good health - Aidsmap

Yes, the same life expectancy as HIV-negative people, but far fewer years in good health  Aidsmap

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in human...

Two PEP doses spaced a week apart protect monkeys from injected HIV; one dose might work in humans  Aidsmap

Could antibodies be used for children with HIV instead of pills? - Aidsmap

Could antibodies be used for children with HIV instead of pills?  Aidsmap

Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV - Aidsmap

Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV  Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV - Aidsmap

Experts shed light on coronavirus response and its implications for people with HIV  Aidsmap

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance be...

The cornerstone of HIV treatment may be losing some of its power: will dolutegravir resistance become a problem?  Aidsmap

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed b...

The amber light: the World Health Organization’s position when an HIV viral load is “suppressed but not undetectable”  Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks - Aidsmap

Fostemsavir salvage therapy continues to look good at 96 weeks  Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it - Aidsmap

At-home support after HIV diagnosis in Uganda helps people get on ART and stick with it  Aidsmap

HIV incidence fell by three-quarters in Australian gay men, with strong association with treatmen...

HIV incidence fell by three-quarters in Australian gay men, with strong association with treatment as prevention  Aidsmap

People with HIV gain weight faster than HIV-negative people - Aidsmap

People with HIV gain weight faster than HIV-negative people  Aidsmap

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity - Aidsmap

Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity  Aidsmap

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure - Aidsmap

Intermittent dosing on HIV dual therapy leads to higher rate of treatment failure  Aidsmap

Long-acting injectable treatment maintains viral suppression - Aidsmap

Long-acting injectable treatment maintains viral suppression  Aidsmap

“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant wom...

“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant women living with HIV  Aidsmap

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy - ...

HIV treatment in the womb helped five South African baby boys to stay undetectable off therapy  Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study - Aidsmap

Therapeutic vaccine shows potential for HIV control off treatment in early study  Aidsmap

The length of time Americans with HIV remain infectious is falling, but slowly - Aidsmap

The length of time Americans with HIV remain infectious is falling, but slowly  Aidsmap

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds...

Four days on, three days off HIV treatment as effective as continuous therapy, French study finds  Aidsmap

Immune modulator clears pre-cancerous anal lesions - Aidsmap

Immune modulator clears pre-cancerous anal lesions  Aidsmap

Ibalizumab, active against highly resistant HIV, now approved in US - Aidsmap

Ibalizumab, active against highly resistant HIV, now approved in US  Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care - Aidsmap

Point-of-care viral load testing improves treatment outcomes and retention in care  Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases - Aidsmap

Adherence counselling reverses viral rebound on dolutegravir in 95% of cases  Aidsmap

African studies show that lowering viral load in the community reduces HIV incidence, but is not ...

African studies show that lowering viral load in the community reduces HIV incidence, but is not enough to eliminate HIV  Aidsmap

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing ...

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy  Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression - Aidsmap

Antiretroviral drug levels in hair strongly predict viral suppression  Aidsmap

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir - Aidsmap

Earlier treatment and higher CD4 counts linked to smaller HIV reservoir  Aidsmap

COVID-19 pandemic has speeded up the implementation of multi-month dispensing - Aidsmap

COVID-19 pandemic has speeded up the implementation of multi-month dispensing  Aidsmap

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys - Aidsmap

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys  Aidsmap

Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women - Aid...

Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women  Aidsmap

Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for ...

Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause  Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America - Aidsmap

Opportunistic infections remain common in people taking HIV treatment in Latin America  Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up - Aidsmap

Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up  Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over - Aidsmap

Switching to Biktarvy maintains viral suppression in people aged 65 or over  Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe - Aidsmap

Progress on 90-90-90 HIV targets shows stark gap between eastern and western Europe  Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV - Aidsmap

Poor adherence associated with disruptive life events in young people living with HIV  Aidsmap

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years - A...

Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years  Aidsmap

Options for two-drug simplification expand - Aidsmap

Options for two-drug simplification expand  Aidsmap

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in N...

Adolescent-centred interventions lead to a 30-percentage-point increase in viral suppression in Namibia, and a 20-percentage-point increase in Nigeria  Aidsmap

Lower CD4 count and unsuppressed HIV raise the risk for severe COVID-19 - Aidsmap

Lower CD4 count and unsuppressed HIV raise the risk for severe COVID-19  Aidsmap

Hepatitis C virtually eliminated in people with HIV in the Netherlands - Aidsmap

Hepatitis C virtually eliminated in people with HIV in the Netherlands  Aidsmap

Antiviral Drugs Market Size, Share, Growth, Forecast, 2034 - Fortune Business Insights

Antiviral Drugs Market Size, Share, Growth, Forecast, 2034  Fortune Business Insights

Fact check: COVID-19 is not a seasonal flu - Reuters

Fact check: COVID-19 is not a seasonal flu  Reuters

Viral suppression in Uganda improved by more viral load tests, done faster - Aidsmap

Viral suppression in Uganda improved by more viral load tests, done faster  Aidsmap